Adenosine is a purine nucleoside composed of a molecule of adenine attached to a ribose sugar molecule (ribofuranose) moiety via a β-N9-glycosidic bond. Derivatives of adenosine are widely found in nature and play an important role in biochemical processes, such as energy transfer—as adenosine triphosphate (ATP) and adenosine diphosphate (ADP)—as well as in signal transduction as cyclic adenosine monophosphate (cAMP). Adenosine itself is a neuromodulator, believed to play a role in promoting sleep and suppressing arousal. Adenosine also plays a role in regulation of blood flow to various organs through vasodilation.
|Trade names||Adenocard; Adenocor; Adenic; Adenoco; Adeno-Jec; Adenoscan; Adenosin; Adrekar; Krenosin|
|Synonyms||SR-96225 (developmental code name)|
(adenosine may be safe to the fetus in pregnant women)
|Bioavailability||Rapidly cleared from circulation via cellular uptake|
|Metabolism||Rapidly converted to inosine and adenosine monophosphate|
|Biological half-life||cleared plasma <30 seconds – half-life <10 seconds|
|Excretion||can leave cell intact or can be degraded to hypoxanthine, xanthine, and ultimately uric acid|
|Chemical and physical data|
|Molar mass||267.241 g/mol|
|3D model (JSmol)|
|(what is this?)|
In addition to adenosine's endogenous forms, it is also used as a medication, specifically, as an antiarrhythmic agent, to treat a number of forms of supraventricular tachycardia that do not improve with vagal maneuvers. Common side effects include chest pain, feeling faint, shortness of breath along with tingling of the senses. Serious side effects include a worsening dysrhythmia and low blood pressure. It appears to be safe in pregnancy.
Diagnosis of supraventricular tachycardiaEdit
When it is administered intravenously, adenosine causes transient heart block in the atrioventricular (AV) node. This is mediated via the A1 receptor, inhibiting adenylyl cyclase, reducing cAMP and so causing cell hyperpolarization by increasing K+ efflux via inward rectifier K+ channels, subsequently inhibiting Ca2+ current. It also causes endothelial-dependent relaxation of smooth muscle as is found inside the artery walls. This causes dilation of the "normal" segments of arteries, i.e. where the endothelium is not separated from the tunica media by atherosclerotic plaque. This feature allows physicians to use adenosine to test for blockages in the coronary arteries, by exaggerating the difference between the normal and abnormal segments.
The administration of adenosine also reduces blood flow to coronary arteries past the occlusion. Other coronary arteries dilate when adenosine is administered while the segment past the occlusion is already maximally dilated. This leads to less blood reaching the ischemic tissue, which in turn produces the characteristic chest pain.
In individuals suspected of suffering from a supraventricular tachycardia (SVT), adenosine is used to help identify the rhythm.
Certain SVTs can be successfully terminated with adenosine. This includes any re-entrant arrhythmias that require the AV node for the re-entry, e.g., AV reentrant tachycardia (AVRT), AV nodal reentrant tachycardia (AVNRT). In addition, atrial tachycardia can sometimes be terminated with adenosine.
Fast rhythms of the heart that are confined to the atria (e.g., atrial fibrillation, atrial flutter) or ventricles (e.g., monomorphic ventricular tachycardia) and do not involve the AV node as part of the re-entrant circuit are not typically converted by adenosine. However, the ventricular response rate is temporarily slowed with adenosine in such cases.
Because of the effects of adenosine on AV node-dependent SVTs, adenosine is considered a class V antiarrhythmic agent. When adenosine is used to cardiovert an abnormal rhythm, it is normal for the heart to enter ventricular asystole for a few seconds. This can be disconcerting to a normally conscious patient, and is associated with angina-like sensations in the chest.
Nuclear stress testEdit
Adenosine is used as an adjunct to thallous (thallium) chloride TI 201 or Tc99m myocardial perfusion scintigraphy (nuclear stress test) in patients unable to undergo adequate stress testing with exercise.
When given for the evaluation or treatment of a supraventricular tachycardia (SVT), the initial dose is 6 mg to 12 mg, depending on standing orders or provider preference, given as a rapid parenteral infusion. Due to adenosine's extremely short half-life, the IV line is started as proximal (near) to the heart as possible, such as the antecubital fossa. The IV push is often followed with an immediate flush of 10-20 ccs of saline. If this has no effect (i.e., no evidence of transient AV block), a dose of 12 mg can be given 1–2 minutes after the first dose. Some clinicians may prefer to administer a higher dose (typically 18 mg), rather than repeat a dose that apparently had no effect.[dubious ] When given to dilate the arteries, such as in a "stress test", the dosage is typically 0.14 mg/kg/min, administered for 4 or 6 minutes, depending on the protocol.
The recommended dose may be increased in patients on theophylline, since methylxanthines prevent binding of adenosine at receptor sites. The dose is often decreased in patients on dipyridamole (Persantine) and diazepam (Valium) because adenosine potentiates the effects of these drugs. The recommended dose is also reduced by half in patients presenting congestive heart failure, myocardial infarction, shock, hypoxia, and/or hepatic or renal insufficiency, and in elderly patients.
Dopamine may precipitate toxicity in a person. Carbamazepine may increase heart block. Dipyridamole potentiates the action of adenosine, requiring the use of lower doses.
Methylxanthines (e.g., caffeine, found in coffee, or theophylline in tea, or theobromine, as found in chocolate) competitively antagonize adenosine's effects; an increased dose of adenosine may be required. By nature of caffeine's purine structure, it binds to some of the same receptors as adenosine. Therefore, with the proviso that theophylline and theobromine cross the blood-brain barrier very poorly (thus, have low CNS effects on the heart), the pharmacological effects of adenosine may be blunted in individuals taking large quantities of methylxanthines.
Common contraindications for adenosine include
- Asthma, traditionally considered an absolute contraindication. This is being contended and it is now considered a relative contraindication (however, selective adenosine antagonists are being investigated for use in treatment of asthma)
- Decompensated heart failure
- Long QT syndrome
- Poison/drug-induced tachycardia
- Second- or third-degree heart block (without a pacemaker)
- Severe hypotension
- Sick sinus syndrome (without a pacemaker)
When administered via a central lumen catheter, adenosine has been shown to initiate atrial fibrillation because of its effect on atrial tissue. In individuals with accessory pathways, the onset of atrial fibrillation can lead to a life-threatening ventricular fibrillation. However, adenosine may be administered if equipment for cardioversion is immediately available as a backup.
Many individuals experience facial flushing, a temporary rash on the chest, lightheadedness, diaphoresis, or nausea after administration of adenosine due to its vasodilatory effects. Metallic taste is a hallmark side-effect of adenosine administration. These symptoms are transitory, usually lasting less than one minute. It is classically associated with a sense of "impending doom", more prosaically described as apprehension. This lasts a few seconds after administration of a bolus dose, during transient asystole induced by intravenous administration. In some cases, adenosine can make patients' limbs feel numb for about 2–5 minutes after administration intravenously depending on the dosage (usually above 12 mg).
Adenosine is an endogenous purine nucleoside that modulates many physiological processes. Cellular signaling by adenosine occurs through four known adenosine receptor subtypes (A1, A2A, A2B, and A3).
Extracellular adenosine concentrations from normal cells are approximately 300 nM; however, in response to cellular damage (e.g. in inflammatory or ischemic tissue), these concentrations are quickly elevated (600–1,200 nM). Thus, in regard to stress or injury, the function of adenosine is primarily that of cytoprotection preventing tissue damage during instances of hypoxia, ischemia, and seizure activity. Activation of A2A receptors produces a constellation of responses that in general can be classified as anti-inflammatory.
In the US, Adenosine is marketed as Adenocard. In India Adenosine is sold as Adenoscan (Cipla)
All adenosine receptor subtypes (A1, A2A, A2B, and A3) are G-protein-coupled receptors. The four receptor subtypes are further classified based on their ability to either stimulate or inhibit adenylate cyclase activity. The A1 receptors couple to Gi/o and decreases cAMP levels, while the A2 adenosine receptors couple to Gs, which stimulates adenylate cyclase activity. In addition, A1 receptors couple to Go, which has been reported to mediate adenosine inhibition of Ca2+ conductance, whereas A2B and A3 receptors also couple to Gq and stimulate phospholipase activity. Researchers at Cornell University have recently shown adenosine receptors to be key in opening the blood-brain barrier (BBB). Mice dosed with adenosine have shown increased transport across the BBB of amyloid plaque antibodies and prodrugs associated with Parkinson's disease, Alzheimer's, multiple sclerosis, and cancers of the central nervous system.
Ghrelin/growth hormone secretagogue receptorEdit
Adenosine is an endogenous agonist of the ghrelin/growth hormone secretagogue receptor. However, while it is able to increase appetite, unlike other agonists of this receptor, adenosine is unable to induce the secretion of growth hormone and increase its plasma levels.
Adenosine deaminase deficiency is a known cause of immunodeficiency.
The adenosine analog NITD008 has been reported to directly inhibit the recombinant RNA-dependent RNA polymerase of the dengue virus by terminating its RNA chain synthesis. This suppresses peak viremia and rise in cytokines and prevented lethality in infected animals, raising the possibility of a new treatment for this flavivirus. The 7-deaza-adenosine analog has been shown to inhibit the replication of the hepatitis C virus. BCX4430 is protective against Ebola and Marburg viruses. Such adenosine analogs are potentially clinically useful since they can be taken orally.
Adenosine is believed to be an anti-inflammatory agent at the A2A receptor. Topical treatment of adenosine to foot wounds in diabetes mellitus has been shown in lab animals to drastically increase tissue repair and reconstruction. Topical administration of adenosine for use in wound-healing deficiencies and diabetes mellitus in humans is currently under clinical investigation.
Central nervous systemEdit
In general, adenosine has an inhibitory effect in the central nervous system (CNS). Caffeine's stimulatory effects are credited primarily (although not entirely) to its capacity to block adenosine receptors, thereby reducing the inhibitory tonus of adenosine in the CNS. This reduction in adenosine activity leads to increased activity of the neurotransmitters dopamine and glutamate. Experimental evidence suggests that adenosine and adenosine agonists can activate Trk receptor phosphorylation through a mechanism that requires the adenosine A2A receptor.
Adenosine has been shown to promote thickening of hair on people with thinning hair. A 2013 study compared topical adenosine to minoxidil in male androgenetic alopecia, finding it was not superior to minoxidil and further trials were needed.
- I.K. Morton; Judith M. Hall (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 106–. ISBN 978-94-011-4439-1.
- J. Buckingham (1987). Dictionary of Organic Compounds. CRC Press. pp. 75–. ISBN 978-0-412-54090-5.
- Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 18–. ISBN 978-3-88763-075-1.
- Sato, A (April 2005). "Mechanism of vasodilation to adenosine in coronary arterioles from patients with heart disease". American Journal of Physiology. Heart and Circulatory Physiology. 288 (4): H1633–40. doi:10.1152/ajpheart.00575.2004. PMID 15772334.
- Costa, F; Biaggioni, I (May 1998). "Role of nitric oxide in adenosine-induced vasodilation in humans". Hypertension. 31 (5): 1061–4. doi:10.1161/01.HYP.31.5.1061. PMID 9576114.
- Morgan, JM; McCormack, DG; Griffiths, MJ; Morgan, CJ; Barnes, PJ; Evans, TW (September 1991). "Adenosine as a vasodilator in primary pulmonary hypertension". Circulation. 84 (3): 1145–9. doi:10.1161/01.CIR.84.3.1145. PMID 1884445.
- "Adenosine". The American Society of Health-System Pharmacists. Retrieved Jan 12, 2015.
- Katzung, Bertram (2012). Basic & Clinical Pharmacology (12th ed.). McGraw Hill. p. 245. ISBN 978-0-07-176402-5.
- Mitchell J, Lazarenko G (November 2008). "Wide QRS complex tachycardia. Diagnosis: Supraventricular tachycardia with aberrant conduction; intravenous (IV) adenosine". CJEM. 10 (6): 572–3, 581. PMID 19000353.
- Pijls, Nico H. J.; Bernard De Bruyne (2000). Coronary Pressure. Springer. ISBN 0-7923-6170-9.
- O'Keefe, JH; Bateman, TM; Silverstri, R; et al. (1992). "Safety and diagnostic accuracy of adenosine thallium-201 scintigraphy in patients unable to exercise and those with left bundle branch block". Am Heart J. 124 (3): 614–21. doi:10.1016/0002-8703(92)90268-z. PMID 1514488.
- "Caffeine". Chemistry Explained.
- "Vitamin B4". R&S Pharmchem. April 2011. Archived from the original on 2011-07-15.
- Brown RA, Spina D, Page CP (March 2008). "Adenosine receptors and asthma". Br. J. Pharmacol. 153 Suppl 1 (S1): S446–56. doi:10.1038/bjp.2008.22. PMC . PMID 18311158.
- Haskó G, Linden J, Cronstein B, Pacher P (September 2008). "Adenosine receptors: therapeutic aspects for inflammatory and immune diseases". Nat Rev Drug Discov. 7 (9): 759–70. doi:10.1038/nrd2638. PMC . PMID 18758473.
- Haskó, G (January 2004). "Adenosine: an endogenous regulator of innate immunity". Trends in Immunology. 25 (1): 33–39. doi:10.1016/j.it.2003.11.003. PMID 14698282.
- Carman, A. J.; Mills, J. H.; Krenz, A; Kim, D. G.; Bynoe, M. S. (2011). "Adenosine receptor signaling modulates permeability of the blood-brain barrier". J. Neurosci. 31 (37): 13272–80. doi:10.1523/JNEUROSCI.3337-11.2011. PMC . PMID 21917810.
- Claude Kordon; I. Robinson; Jacques Hanoune; R. Dantzer (6 December 2012). Brain Somatic Cross-Talk and the Central Control of Metabolism. Springer Science & Business Media. pp. 42–. ISBN 978-3-642-18999-9.
- Miller-Patrick K, Vincent DL, Early RJ, et al. (1993). "Effects of the purine biosynthesis pathway inhibitors azaserine, hadacidin, and mycophenolic acid on the developing ovine corpus luteum". Chin J Physiol. 36 (4): 245–52. PMID 8020339.
- Yin, Z; Chen, YL; Schul, W; Wang, QY; Gu, F; Duraiswamy, J; Reddy Kondreddi, R; Niyomrattanakit, P; Lakshminarayana, SB; Goh, A; Xu, HY; Liu, W; Liu, B; Lim, JY; Ng, CY; Qing, M; Lim, CC; Yip, A; Wang, G; Chan, WL; Tan, HP; Lin, K; Zhang, B; Zou, G; Bernard, KA; Garrett, C; Beltz, K; Dong, M; Weaver, M; He, H; Pichota, A; Dartois, V; Keller, TH; Shi, PY (2009). "An adenosine nucleoside inhibitor of dengue virus". Proc Natl Acad Sci U S A. 106 (48): 20435–20439. Bibcode:2009PNAS..10620435Y. doi:10.1073/pnas.0907010106. PMC . PMID 19918064.
- Olsen, DB; Eldrup, AB; Bartholomew, L; Bhat, B; Bosserman, MR; Ceccacci, A; Colwell, LF; Fay, JF; Flores, OA; Getty, K. L.; Grobler, J. A.; Lafemina, R. L.; Markel, E. J.; Migliaccio, G.; Prhavc, M.; Stahlhut, M. W.; Tomassini, J. E.; MacCoss, M.; Hazuda, D. J.; Carroll, S. S. (2004). "A 7-Deaza-Adenosine Analog Is a Potent and Selective Inhibitor of Hepatitis C Virus Replication with Excellent Pharmacokinetic Properties". Antimicrobial Agents and Chemotherapy. 48 (10): 3944–53. doi:10.1128/AAC.48.10.3944-3953.2004. PMC . PMID 15388457.
- Warren, T. K.; Wells, J.; Panchal, R. G.; Stuthman, K. S.; Garza, N. L.; Van Tongeren, S. A.; Dong, L.; Retterer, C. J.; Eaton, B. P.; Pegoraro, G.; Honnold, S.; Bantia, S.; Kotian, P.; Chen, X.; Taubenheim, B. R.; Welch, L. S.; Minning, D. M.; Babu, Y. S.; Sheridan, W. P.; Bavari, S. (2014). "Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430". Nature. 508 (7496): 402–5. Bibcode:2014Natur.508..402W. doi:10.1038/nature13027. PMID 24590073.
- Nakav S, Chaimovitz C, Sufaro Y (2008). Bozza P, ed. "Anti-Inflammatory Preconditioning by Agonists of Adenosine A1 Receptor". PLoS ONE. 3 (5): e2107. Bibcode:2008PLoSO...3.2107N. doi:10.1371/journal.pone.0002107. PMC . PMID 18461129.
- Trevethick MA, Mantell SJ, Stuart EF, Barnard A, Wright KN, Yeadon M (October 2008). "Treating lung inflammation with agonists of the adenosine A2A receptor: promises, problems and potential solutions". Br. J. Pharmacol. 155 (4): 463–74. doi:10.1038/bjp.2008.329. PMC . PMID 18846036.
- Cronstein B (2010). "How does methotrexate suppress inflammation?". Clin Exp Rheumatol. 28 (5 Suppl 61): S21–3. PMID 21044428.
- Lee, FS; Chao, MV; Lee (March 2001). "Activation of Trk neurotrophin receptors in the absence of neurotrophins". PNAS. 98 (6): 3555–3560. Bibcode:2001PNAS...98.3555L. doi:10.1073/pnas.061020198. PMC . PMID 11248116.
- Oura, H; Iino, M; Nakazawa, Y; Tajima, M; Ideta, R; Nakaya, Y; Arase, S; Kishimoto, J (December 2008). "Adenosine increases anagen hair growth and thick hairs in Japanese women with female pattern hair loss: a pilot, double-blind, randomized, placebo-controlled trial". The Journal of dermatology. 35 (12): 763–7. doi:10.1111/j.1346-8138.2008.00564.x. PMID 19239555.
- Hwang, KA; Hwang, YL; Lee, MH; Kim, NR; Roh, SS; Lee, Y; Kim, CD; Lee, JH; Choi, KC (February 2012). "Adenosine stimulates growth of dermal papilla and lengthens the anagen phase by increasing the cysteine level via fibroblast growth factors 2 and 7 in an organ culture of mouse vibrissae hair follicles". International journal of molecular medicine. 29 (2): 195–201. doi:10.3892/ijmm.2011.817. PMID 22020741.
- Faghihi, G; Iraji, F; Rajaee Harandi, M; Nilforoushzadeh, M. A.; Askari, G (2013). "Comparison of the efficacy of topical minoxidil 5% and adenosine 0.75% solutions on male androgenetic alopecia and measuring patient satisfaction rate". Acta Dermatovenerol Croat. 21 (3): 155–9. PMID 24183218.